RE:RE:Today's Announcement consultant99 wrote: It remains to be seen how much money will actually be spent between now and say Q1 of 2023 for NSCLC and GBM development.
As far as the completion of the Phase 2 Bladder cancer trial it was my understanding the company had sufficient funds to complete the trial as per management notes.
Due to the Covid related delays I assumed that meant there were sufficient funds to get through the first 25 patients required to achieve FDA approval for BTD and AA (not necessarily to complete the full trial). Once the company gets AA the trial should be self-sustaining should it not?
Anyways the PR is vague enough that the money can be used for just about anything the company is doing right now. As far as deliverables the company is way behind their original timetable for human trials. So what exactly does this raise mean for development of alternative cancer treatments; asking for a friend?
I think that is correct 99,
I don't know exactly what the $$ will be used for. But I think they will focus on the GLP and new Phase 1s. and new NMIBC patients that come into the Phase 2 trial. Before too long we should be a multiple indication cancer stock :-)
IF Covid vaxx happens it should be PHAC that takes care of future funding for that. Includig a nice check going to TLT.